RELA and B-cell chronic lymphocytic leukemia: When B-CLL samples were treated with MLN4924 or the ubiquitin-activation enzyme inhibitor MLN7243/TAK243 ex vivo, we did not observe any variation in GSK-3 or p65 protein expression (Figure 1D).